Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q2 2022 Earnings Conference Call August 5, 2022 8:30 AM ET
Company Participants
Anthony DiMeo - Senior Director of Investor Relations
Chirag Patel - Co-Founder, Co-Chief Executive Officer, President & Director
Chintu Patel - Co-Founder & Co-Chief Executive Officer
Anastasios Konidaris - Executive Vice President & Chief Financial Officer
Harsher Singh - Head of Biosciences
Jason Daly - Senior Vice President, Chief Legal Officer & Corporate Secretary
Conference Call Participants
Balaji Prasad - Barclays
Nathan Rich - Goldman Sachs
David Amsellem - Piper Sandler
Gary Nachman - BMO Capital Markets
Greg Fraser - Truist Securities
Elliot Wilbur - Raymond James
Ekaterina Knyazkova - JPMorgan
Operator
Hello and welcome to today's Amneal 2Q 2022 Earnings Conference Call. My name is Elliot and I will be coordinating your call today. [Operator Instructions]
I would now like to turn the call over to Amneal’s Head of Investor Relations, Tony DiMeo.
Anthony DiMeo
Good morning and thank you for joining Amneal's Second Quarter 2022 Earnings Call. Today, we issued a press release reporting our financial results. The press release and presentation are available at amneal.com and a replay of this call will be posted after the call.
Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please review the section entitled Cautionary Statements on Forward-Looking Statements in the earnings presentation and our SEC filings for a discussion of factors that may impact our future performance. We also discuss non-GAAP measures. Important information on our use of these measures in reconciliation to U.S. GAAP may be found in the earnings presentation.
On the call today are Chirag and Chintu Patel, Co-CEOs; Tasos Konidaris, CFO; Andy Boyer, Generics; Harsher Singh, Biosciences; and
- Read more current AMRX analysis and news
- View all earnings call transcripts